In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 26 to 50 of 342

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance	TBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]	Technology appraisal guidance	3 September 2026
Avelumab for previously treated platinum-resistant ovarian cancer ID1497	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]	Technology appraisal guidance	TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance	TBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]	Technology appraisal guidance	TBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]	Technology appraisal guidance	TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]	Technology appraisal guidance	TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]	Technology appraisal guidance	21 January 2026
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]	Technology appraisal guidance	11 February 2026
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]	Technology appraisal guidance	TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]	Technology appraisal guidance	8 December 2027
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance	13 January 2027
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	TBC
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance	15 July 2026
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537	Technology appraisal guidance	26 August 2026
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance	TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]	Technology appraisal guidance	TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC

Results per page

10
25
50
All